Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Name: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Published: 2023
License: Public Domain

M.D. Anderson Cancer Center · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

brain metastases, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Related documents